Nuwellis Announces Closing of $6.0 Million Registered Public Offering

Nuwellis (NASDAQ: NUWE), a medical technology company focused on cardiorenal conditions, announced the successful closing of a $6.0 million registered public offering. The offering included 1.9 million shares of common stock and pre-funded warrants, with accompanying Series C and D warrants. The public offering price was $0.30 per share with accompanying warrants.

06/08/2026, 9:46 PM • Benzinga

Nuwellis Announces Closing of $6.0 Million Registered Public Offering

Nuwellis, Inc. (Nasdaq: NUWE) announced the successful closing of a public offering raising approximately $6.0 million through the sale of 1,903,338 shares of common stock and pre-funded warrants, along with Series C and D warrants. The offering was priced at $0.30 per share with accompanying warrants. Ladenburg Thalmann & Co. Inc. served as the sole book-running manager.

06/08/2026, 9:46 PM • GlobeNewswire

Nuwellis, Inc. Announces First Quarter 2026 Financial Results

Nuwellis, Inc. (NUWE) reported Q1 2026 net sales of $2.4 million, up 26% year-over-year, with gross margin improving to 70.1%. The company completed the Rendiatech acquisition, appointed new CFO and board members, and expanded commercial coverage. However, the company posted a net loss of $4.3 million and held only $2.2 million in cash with no debt.

05/12/2026, 8:00 AM • GlobeNewswire

Nuwellis Completes Acquisition of Rendiatech

Nuwellis (NASDAQ: NUWE) has completed its acquisition of Rendiatech, an Israeli developer of automated kidney function monitoring technology. The acquisition expands Nuwellis' capabilities in fluid management and kidney function monitoring, complementing its existing Aquadex SmartFlow System. The technology enables continuous renal monitoring with real-time data capture to support clinical decision-making in critically ill patients.

03/17/2026, 8:00 AM • Benzinga

Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio Strategy

Nuwellis (NASDAQ: NUWE) announced a definitive agreement to acquire Rendiatech Ltd., an Israeli medical technology company specializing in automated kidney function monitoring. The acquisition expands Nuwellis' cardiorenal portfolio beyond therapeutic fluid management into real-time renal diagnostics, leveraging Rendiatech's Clarity system for continuous urine-output measurement. The transaction is expected to close following customary conditions and will be integrated using Nuwellis' existing commercial infrastructure.

01/29/2026, 4:35 PM • Benzinga

Nuwellis Signs Letter of Intent to Explore Acquisition of Rendiatech Ltd., A Real-Time Fluid Monitoring Company

Nuwellis has signed a non-binding letter of intent to acquire Rendiatech, an Israeli medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies, potentially expanding its fluid management technology platform.

08/19/2025, 8:15 AM • Benzinga

Nuwellis Stockholders Approve All Proposals at Special Meeting

Nuwellis held a Special Meeting of Stockholders, where shareholders approved proposals to increase authorized shares, potentially conduct a reverse stock split, and issue shares from a recent financing to enhance financial flexibility.

08/04/2025, 5:24 PM • GlobeNewswire

Why Nuwellis Shares Are Exploding Today: A 200% Surge Explained

Nuwellis Inc experienced a dramatic 200% stock surge in premarket trading after receiving a new U.S. patent for an improved extracorporeal blood filtering machine that enhances fluid balance calculation accuracy in continuous renal replacement therapy systems.

07/16/2025, 10:07 AM • Investing

Why Nuwellis Shares Are Exploding Today: A 200% Surge Explained

Nuwellis Inc experienced a dramatic 200% stock surge in premarket trading after receiving a new U.S. patent for an innovative extracorporeal blood filtering machine that improves fluid balance calculation accuracy in continuous renal replacement therapy systems.

07/16/2025, 9:31 AM • Investing

Nuwellis Soars 31.25% In After-Hours Trading — What's Behind The Surge?

Nuwellis experienced a significant stock price surge of 31.25% in after-hours trading following the announcement of securing a key patent for its fluid management technology and bringing back veteran CEO John Erb.

07/16/2025, 1:38 AM • Benzinga